Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 9 versus UROVIST CYSTO PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 9 versus UROVIST CYSTO PEDIATRIC.
OMNIPAQUE 9 vs UROVIST CYSTO PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated nonionic contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. Its iodine content (350 mg/mL) provides radiopacity, while low osmolality reduces adverse hemodynamic effects.
Radiopaque contrast agent that provides enhanced visualization of the urinary tract by attenuating X-rays due to its iodine content.
Omnipaque 9 (iohexol 9 mg I/mL) is administered intravenously. For CT enhancement, typical adult dose is 50-100 mL (450-900 mg I) by slow IV injection.
Not applicable; Urovist Cysto Pediatric is a contrast agent for cystourethrography, instilled intravesically as a single dose of 5-10 mL for infants and 10-30 mL for children, not a systemic drug.
None Documented
None Documented
Terminal elimination half-life: 1–2 hours in patients with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
After intravesical administration, systemic absorption is minimal; therefore, a meaningful terminal half-life is not defined. If absorbed, the elimination half-life of diatrizoate is approximately 1–2 hours in patients with normal renal function, reflecting rapid renal clearance.
Renal: >95% unchanged via glomerular filtration; fecal: <1%.
Urovist Cysto Pediatric (diatrizoate meglumine) is not significantly absorbed systemically after intravesical administration. The small fraction absorbed is excreted unchanged in urine via glomerular filtration, with 95% eliminated within 24 hours after intravenous administration; biliary/fecal excretion is negligible.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent